Roivant Sciences LTD Form 4 insider transactions

Roivant Sciences Ltd.'s CFO, Richard Pulik, reported the disposition of 1,653 common shares at $11.39 per share on June 28, 2025, to cover tax withholding obligations related to vested restricted stock units.

Roivant Sciences Ltd. Director and 10% Owner Daniel Allen Gold reported an in-kind distribution of over 36 million common shares from various investment entities for no consideration, alongside an update on his total beneficial ownership including vested restricted stock units.

Roivant Sciences Ltd. Director Keith S. Manchester filed a Form 4 detailing an upcoming pre-scheduled in-kind share distribution from QVT entities and the future vesting of his restricted stock units.

QVT Financial LP, a significant shareholder and insider of Roivant Sciences Ltd., has filed a Form 4 detailing a planned in-kind distribution of common shares among its affiliated entities, effective June 25, 2025.

Roivant Sciences Ltd. CFO Richard Pulik reported the disposition of 1,503 common shares at $11.45 each, primarily for tax withholding obligations related to vested Restricted Stock Units (RSUs).

Roivant Sciences Ltd.'s President and COO, Eric Venker, executed a pre-planned transaction, exercising stock options and subsequently selling 100,000 common shares.

Roivant Sciences Ltd. Director and 10% owner Vivek Ramaswamy reported the sale of over 1.1 million common shares in two separate transactions in mid-June 2025.

Roivant Sciences Ltd. Director and 10% owner Vivek Ramaswamy reported the sale of 748,230 common shares across two transactions in early June 2025, totaling approximately $8.45 million.

Roivant Sciences Ltd.'s President and COO, Eric Venker, exercised a substantial number of stock options and subsequently sold common shares for over $11 million in early June 2025.

Roivant Sciences Ltd.'s CFO, Richard Pulik, disposed of 1,653 common shares at $10.62 each to cover tax withholding obligations related to RSU vesting.

Richard Pulik, CFO of Roivant Sciences Ltd., reports the disposal of 3,487 common shares to cover tax withholding obligations related to vested RSUs.

Eric Venker, President & COO of Roivant Sciences, exercised stock options and sold 100,000 common shares on May 20, 2025, while also settling RSUs for tax obligations.

Matthew Gline, CEO of Roivant Sciences, reports the disposal of shares to cover tax obligations related to vested RSUs.

Vivek Ramaswamy, a director and 10% owner of Roivant Sciences Ltd., sold a significant number of common shares over two days in May 2025.

Richard Pulik, CFO of Roivant Sciences, reports a transaction involving the net settlement of Restricted Stock Units (RSUs) to cover tax obligations.

Richard Pulik, CFO of Roivant Sciences Ltd., reports the acquisition of restricted stock units and stock options.

Eric Venker, President & COO of Roivant Sciences, reports the acquisition and disposal of common shares and stock options, including transactions to cover tax obligations and sales under a Rule 10b5-1 trading plan.

Matthew Gline, CEO of Roivant Sciences, reports the disposal of shares to cover tax obligations related to vested RSUs.

Melissa B. Epperly, a director of Roivant Sciences Ltd., reports acquiring 1,847 common shares as part of the company's Non-Employee Director Compensation Plan.

James C. Momtazee, a director of Roivant Sciences Ltd., reports acquisition and disposal of common shares to satisfy tax obligations.

Director Ilan Oren reports acquisition and disposal of Roivant Sciences Ltd. common shares related to director compensation and tax obligations.

Richard Pulik, CFO of Roivant Sciences, reports the disposal of 1,653 common shares to cover tax obligations related to vested RSUs.

Eric Venker, President & COO of Roivant Sciences, exercised stock options and sold shares to cover tax obligations and for trading purposes under a pre-arranged 10b5-1 plan.

Jennifer Humes, Chief Accounting Officer of Roivant Sciences Ltd., reports the acquisition of common shares and stock options.

Richard Pulik, CFO of Roivant Sciences, reports a transaction involving the disposal of common shares to cover tax obligations related to vested RSUs.

Roivant Sciences CEO Matthew Gline disposed of 10,945 common shares to cover tax obligations related to vested RSUs.

Richard Pulik, CFO of Roivant Sciences Ltd., disposed of 1,635 common shares on February 28, 2025, to cover tax withholding obligations related to vested RSUs.

Rakhi Kumar, Chief Accounting Officer of Roivant Sciences, reports a transaction involving the disposal of common shares to cover tax obligations related to vested RSUs.

Roivant Sciences CEO Matthew Gline disposed of 10,945 common shares to cover tax obligations related to vested RSUs.

Eric Venker, President & COO of Roivant Sciences, exercised stock options and sold 100,000 common shares at a weighted average price of $10.65 on February 20, 2025.